Articles tagged with Huntingtons Disease
An interdisciplinary team from Erlangen has found a new treatment for Huntington's disease by accelerating the degradation of a specific messenger molecule necessary for protein synthesis. This reduces the huntingtin level in patients, offering new hope for long-term implementation of RNA-modifying approaches for fatal diseases.
A new study reveals how aging triggers a loss of crucial autophagy in neurons affected by Huntington's disease. Enhancing autophagy with a chemical compound called G2 protects these cells from death, suggesting a potential treatment for the condition.
Researchers developed a machine learning model to quickly recognize predictive risk factors and their importance for undesirable hospitalization outcomes. The model achieved an accuracy of 95.6% and identified modifiable risk factors that can be mitigated through clinical interventions.
A University at Buffalo-led study suggests the huntingtin protein is involved in neuronal injury and regeneration. The research found that HTT moves from the injury site to the cell body, carrying components necessary for survival.
Researchers established a novel strategy to treat Huntington's disease by converting the disease-causing form of the huntingtin protein into its disease-free form. This process maintains the original function of the protein, offering a new approach to tackle the neurodegenerative disorder.
A new study identifies how the suppression of a specific transcription gene triggers changes that impair oligodendrocyte function in Huntington's disease. The researchers believe replacing or fixing defective glia cells may prove a far easier proposition than replenishing neurons lost in the disease.
Researchers at Lund University have developed a new method for studying Huntington’s disease by reprogramming skin cells into aged neurons. The results show several defects that explain some of the disease mechanisms in neurons from patients with Huntington’s disease, including problems with protein breakdown and recycling. This innova...
Researchers found substantial iron deposits in motor circuits of the brain in individuals with high genetic risk for hereditary hemochromatosis, increasing risk for Parkinson's disease and other movement disorders. Males were more affected than females due to natural processes.
A novel staging framework assesses Huntington's Disease progression and enables early-stage clinical trials of drugs. The HD-ISS groups patients by biological, clinical, and functional characteristics, allowing researchers to evaluate therapeutics in the earliest stages of disease.
Research reveals pridopidine enhances autophagy in ALS model, reducing toxic protein aggregation and promoting neuronal health. The study supports pridopidine's potential as a treatment for neurodegenerative diseases like Huntington's disease and Alzheimer's.
Researchers have developed a process to convert non-neuronal cells into functioning neurons that can take up residence in the brain and restore capacities undermined by Parkinson's destruction of dopaminergic cells. In a proof-of-concept study, one group of experimentally engineered cells performs optimally in terms of survival, growth...
A new study found that valbenazine, a VMAT2 inhibitor, is safe and effective in treating chorea in patients with Huntington's disease. Chorea is a common symptom of the disease, causing involuntary and irregular movements.
A new study shows that a potential treatment for Alzheimer's disease, sargramostim, improves cognitive function in people with Down syndrome and normal aging mice. The drug reverses learning and memory deficits, nerve cell loss, and brain abnormalities in mouse models of Down syndrome and aging.
A recent study found that stimulating reactive astrocytes promotes the elimination of toxic protein aggregates in Huntington's disease. This cooperative mechanism between neurons and astrocytes holds promise for potential treatments.
A new DNA test has been developed to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more accurately than existing tests. The test uses Nanopore sequencing technology to scan for abnormally long repeats within patients' genes, which are the hallmarks of disease.
A team of researchers from MIT created a comprehensive atlas of cerebrovascular cells in human brain tissue, identifying 11 subtypes and their functions. The study reveals differences between healthy and diseased cells, potentially leading to new targets for treating Huntington's disease.
Researchers have developed a new mouse model of Huntington's disease that recapitulates more disease-like characteristics than earlier models. The study provides new clues to the mystery surrounding genetic mutations and gives researchers a powerful tool to test new therapies.
A new study found that aging and disease alter body temperature rhythms in mice, mirroring the disruption seen in humans. In young, healthy mice, daytime temperatures were lower than nighttime temperatures, but this difference disappeared in older, diseased animals.
Researchers have used advanced microscopy to study the ultrastructure of huntingtin inclusions, revealing different mechanisms of aggregation that lead to distinct biochemical properties. The findings suggest targeting inclusion growth as a potential therapeutic strategy for slowing Huntington's disease progression.
A new study found that toxic fatty acids produced by astrocytes can trigger cell death in damaged neurons, which may contribute to neurodegenerative diseases such as glaucoma and Alzheimer's. Blocking the production of these fatty acids in mice preserved 75% of neurons, suggesting a promising target for treatment.
Researchers have detected the earliest effects of Huntington's disease in the first two weeks of human embryonic development. The findings suggest that the disease process starts decades earlier than previously thought, and point to new approaches for finding treatments.
A new study from Lund University reveals that psychiatric and cognitive symptoms emerge at an early stage in Huntington's disease, highlighting the importance of targeting the emotional brain. Researchers identify changes in oligodendrocytes and white matter in the limbic system, suggesting a need for new treatment approaches.
Researchers identified a new mechanism preventing toxic DNA lesions in cells, which could lead to therapies for Huntington's disease. The study found that FAN1 can block the accumulation of DNA mismatch repair factors, alleviating toxicity in cells derived from patients.
Scientists developed a new mouse line to study protein balance and quality control in the mammalian brain. The research revealed that different neurodegenerative diseases have distinct protein misfolding patterns, offering insights into potential therapeutic options.
Researchers at Johns Hopkins Medicine report a potential noninvasive biomarker for tracking gene editing therapies in early-stage Huntington's disease. By measuring blood volume in the brain, they found that suppressing the mutant huntingtin gene can normalize altered arteriolar blood volumes and delay or prevent symptom development.
An international study found that the protein PRMT6 ensures transport along axons, and its loss leads to neural impairment. Increasing PRMT6 expression may restore huntingtin function and improve neural health in patients with Huntington's disease.
Simonetta Sipione's research aims to clarify the therapeutic role of gangliosides in the brain, which help brain cells communicate with each other and the environment. The project seeks to develop a viable treatment that tackles the root cause of neurodegenerative diseases like Huntington's and Parkinson's.
A new study published in Nature Communications shows that the mutated huntingtin protein slows brain cells' protein-building machines, called ribosomes, by two to four-fold. This slowing effect ultimately leads to cell death in Huntington's disease.
Researchers found that Huntington's disease worsens due to a degradation of cells' health maintenance systems. The 'Geomic' analysis identified specific gene networks governing molecular pathways that can be targeted to sustain brain cell health.
Researchers at the University of Barcelona have identified small RNAs as a potential therapeutic target for Huntington's disease, which could lead to new treatments and biomarkers. The study reveals that sRNAs play a crucial role in the progression of the disease, including neurotoxicity and neuronal loss.
Researchers have made progress in understanding how heat shock proteins interact with faulty proteins in Huntington's disease, potentially leading to new treatments. The study suggests that these proteins can be activated to prevent protein aggregates from forming.
A study published in EMBO Molecular Medicine reveals that alterations in lamin B1 protein contribute to neurodegeneration in Huntington's disease. The researchers used innovative techniques like FANSI and ChIP-sequencing to analyze the impact of lamin B1 levels on gene transcription.
A two-year longitudinal study measures Huntington's disease-linked proteins mHTT and NfL in controls, mutation carriers, and patients. Levels of NfL rise faster in mutation carriers, while those with high mHTT and NfL show faster progression and more severe brain atrophy.
Researchers have discovered a genetic connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), with the same huntingtin mutation associated with Huntington's disease. The study opens up possibilities for gene therapy targeting this mutation, which could lead to personalized medicine.
Scientists at Scripps Research have developed a new strategy to treat RNA-repeat expansion disorders, which affect millions of people worldwide. The compound has shown promise in early tests against myotonic dystrophy 1 and Fuchs endothelial corneal dystrophy by neutralizing toxic RNAs and preventing their capture of essential proteins.
Researchers demonstrate that one dose of RNA-targeting CRISPR-Cas9 gene therapy can nearly completely reverse symptoms in a mouse model of myotonic dystrophy, reducing toxic RNA buildup by over 50%. This approach holds promise for treating other genetic diseases caused by repetitive RNA buildup.
A world-first study found altered gut bacteria in people with Huntington's disease, associated with symptoms and disease progression. The research raises the possibility of targeting gut bacteria for future treatment.
Scientists have identified an enzyme called TBK1 that can play a central role in treating Huntington's Disease. The enzyme regulates the degradation and clearance of the huntingtin protein, introducing chemical modifications that block its aggregation.
Researchers uncover how the huntingtin protein transports vital materials within neurons, revealing a potential avenue for therapeutics aimed at improving endosomal transport in Huntington's disease patients. The study also highlights the importance of understanding the protein's normal function to develop effective treatments.
Researchers found that misrouted mitochondrial RNA triggers an immune response, leading to cell death in spiny projection neurons ravaged by Huntington's disease. The study also identified a master regulator of gene transcription alterations and matched human brain samples with mouse models.
Researchers at the University of Bristol have identified a novel protein pathway in several human neurodegenerative diseases, including Huntington's disease. Abnormal expression of SAFB1 was found to be associated with spinocerebellar ataxias and polyglutamine expansion, offering new potential diagnostic markers and therapeutic targets.
A monoclonal antibody targeting mutant huntingtin protein effectively binds and depletes the protein from cell culture supernatants, blocking its secretion and uptake. This suggests that mAB C6-17 could interfere with pathological processes of mutant huntingtin spreading in vivo.
A new study from UCL-led researchers has identified the earliest brain changes due to Huntington's disease, detecting damage 24 years before clinical symptoms appear. The findings provide vital insights into the optimal time to initiate treatments, potentially delaying or preventing neurodegeneration.
Researchers found that Huntington's model mice bred to lack IL-6 exhibited exacerbated symptoms compared to those with IL-6. Gene expression differences revealed reduced synaptic signaling pathways in IL-6 deficient mice.
A natural amino acid called arginine has been identified as a potential new treatment for polyglutamine diseases. The study found that arginine improved neurological symptoms in mice with polyQ diseases before and after symptom onset, suggesting its therapeutic potential.
A novel gene therapy has been developed to regenerate functional new neurons in mouse models of Huntington's Disease, offering a potential treatment for the condition. The therapy uses NeuroD1-based gene therapies to convert brain internal glial cells into functional new neurons.
A compound called Naphthyridine-Azaquinolone (NA) has been found to reverse the length of DNA repeat expansions that cause Huntington's disease in a mouse model and cells from individuals affected by the disease. The study suggests NA could be a potential drug therapy for individuals who inherit the disease.
Researchers used a genetic screen to identify genes essential for neuron survival, including those involved in cellular metabolism. The study also uncovered new targets for treating Huntington's disease, such as the Nme gene family.
A new study reveals that neurons in the striatum require the huntingtin gene for regulating movement, maintaining cell health, and developing connections between cells. This discovery may provide a new avenue against Huntington's disease, which affects motor control, dementia, and psychiatric symptoms.
A new technique uses spectroscopy to identify biomarker patterns in blood samples, allowing for improved diagnosis and tracking of Huntington's disease progression. The breakthrough has the potential to lead to better ways to track treatment effects.
The University of Iowa will expand its decade-long study on brain development in children at risk for Huntington's Disease (HD) with a new $18 million NIH grant. Researchers found that children as young as 6 years old had abnormalities in the striatum, an area known to deteriorate in HD, suggesting compensatory mechanisms.
A study published in Brain reveals that an increase in proteinaceous synthesis is linked to the degeneration of affected neurons in Huntington's disease. This finding could lead to the development of new therapies targeting this process.
A new motor assessment tool, Q-Motor, has shown promise in evaluating Huntington's disease in young children, detecting subtle changes in motor ability. The test measures tapping speed and regularity using force transducers and 3-D position sensors, and can also assess grasping and lifting abilities.
Researchers analyzed brain samples from two mutant HD gene positive individuals and found massive inflammation and similar gene expression patterns in the striatum compared to the prefrontal cortex. Unique patterns were also observed in the striatum, suggesting active neurogenesis during the disease process.
A study led by UCLA researchers found that suppressing the mutation in astrocytes can stop the progression of Huntington's disease in mice and repair some of the damage. The findings suggest that impaired astrocytes play a role in many neurological diseases, including Alzheimer's and ALS.
Researchers found that Cdk5 kinase hyperfunction alters the signalling pathway of DARPP-32/β-adducin in the nucleus accumbens brain region, leading to depressive-like behavior in Huntington's disease models. The study suggests new molecular pathways for treating depression in people with Huntington's.
A new study reveals that up to 90% of individuals at risk for Huntington's disease choose not to take a gene test, primarily due to uncertainty about treatment options and the inability to undo the knowledge. The study suggests that supportive counseling is necessary to help these individuals make informed decisions.
Researchers have identified a genetic variant influencing the age of onset in Huntington disease, beyond just the length of the expansion mutation. This new predictor may enable families with additional information and improve disease management by providing genetic counsellors with valuable data.
A study published in Human Molecular Genetics reveals that DNA mutations trigger an inflammatory response, leading to cell death and progressive neurological damage. The discovery may lead to effective treatments using existing anti-inflammatory drugs.
Scientists at Scripps Research have discovered that the Rhes protein creates tunnel-like nanotubes that enable the toxic Huntington's protein to travel between neurons, contributing to brain cell destruction and disease progression. This finding improves understanding of how Huntington's disease attacks certain brain cells.